Anti-tumour necrosis factor therapy: can we afford it?
نویسندگان
چکیده
منابع مشابه
Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?
Controlled trials have confirmed the efficacy of two tumour necrosis factor α (TNF-α) antibodies in active Crohn’s disease. In responding patients, the therapeutic effects qualitatively differ from those observed with standard therapy, including corticosteroids and immunosuppressives, and complete clinical remission can be induced in about one third of patients that did not respond to standard ...
متن کاملMycobacterial diseases developed during anti-tumour necrosis factor-α therapy.
Nontuberculous mycobacterial (NTM) disease and tuberculosis (TB) develop during anti-tumour necrosis factor (TNF)-α therapy. We compared clinical characteristics and outcomes between the two diseases. A total of 1165 patients were screened for TB and treated with TNF-α antagonists from July 2004 to July 2013 for the following conditions: inflammatory bowel disease (n = 422), rheumatoid arthriti...
متن کاملAnti-Tumour Necrosis Factor-α Therapy in Crohn’s Disease
Crohn’s disease is a chronic, relapsing, inflammatory disease of the gastro-intestinal tract. Manifestations of the disease may be severe, and lead to long-term therapy with a variety of medications and/or surgery. There are two main classifications of the disease, including the relapsing-remitting chronic active variety, and the penetrating or fistulising variety. Tumour necrosis factor-alpha ...
متن کاملAnti-tumour necrosis factor therapy in seronegative spondyloarthritis.
S19–23. 13 Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004;232:560–7. 14 Wells AU, Hansell DM, Haslam PL, Rubens MB et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fi...
متن کاملPlatform process will give platform product - Can we afford it?
Introduction Manufacturing processes for therapeutic monoclonal antibodies (mAbs) have evolved immensely in the past two decades around two major thrust areas. 1) Advancements in a) Cell line developmentbreakthrough and incremental knowledge gain in technology b) Media and feed formulation strategies c) Advent of Disposables and Instrumentation technologies thus offering significant improvement...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the Rheumatic Diseases
سال: 2005
ISSN: 0003-4967
DOI: 10.1136/ard.2005.037564